loader
Find a Test

Factor VIII Inhibitor Profile Comprehensive

Order Code
117157
CPT
85240, 85730, 85732x3
Test Details
Synonyms

Bethesda Titer

TAT

7 days

Methodology

The factor VIII inhibitor (Bethesda titer) assay is performed using an activated partial thromboplastin time (aPTT)-based test system.6 Serial dilutions are made of patient plasma with veronal buffered saline, then mixed with normal plasma containing close to 100% factor VIII activity and are then incubated for one hour. An aPTT-based factor VIII assay using factor VIII-depleted plasma substrate is then performed on these incubated mixtures. Results are compared to those of incubated normal plasma. One Bethesda unit is defined as the amount of factor VIII inhibitor that neutralized 0.5 IU of factor VIII in this system. The number of serial dilutions tested is based on the anticipated level of the inhibitor.

Remarks

Test Includes: Activated partial thromboplastin time (aPTT), aPTT 1:1 mix with normal plasma, aPTT 1:1 incubated mix with normal plasma, aPTT 1:1 mix with saline, factor VIII activity, factor VIII Bethesda titer

Performing Location

Accredited Laboratory Partner

Testing Frequency

Contact Technical Support

Test Overview

Comprehensive evaluation for Factor VIII inhibitors, including titer and response. Used in advanced Hemophilia A cases.

Specimen Type

Plasma

Volume

3 mL

Specimen Container

Blue top (sodium citrate) tube

Patient Preparation

No special preparation is required for this test. You may eat, drink, and take your medications as normal, unless instructed otherwise by your healthcare provider.

Collection

Citrated Plasma samples should be collected by double centrifugation

Specimen Stability
Temperature Period
Frozen Contact Technical Support
Order Code
117157
CPT
85240, 85730, 85732x3
Test Details
Synonyms

Bethesda Titer

TAT

7 days

Methodology

The factor VIII inhibitor (Bethesda titer) assay is performed using an activated partial thromboplastin time (aPTT)-based test system.6 Serial dilutions are made of patient plasma with veronal buffered saline, then mixed with normal plasma containing close to 100% factor VIII activity and are then incubated for one hour. An aPTT-based factor VIII assay using factor VIII-depleted plasma substrate is then performed on these incubated mixtures. Results are compared to those of incubated normal plasma. One Bethesda unit is defined as the amount of factor VIII inhibitor that neutralized 0.5 IU of factor VIII in this system. The number of serial dilutions tested is based on the anticipated level of the inhibitor.

Remarks

Test Includes: Activated partial thromboplastin time (aPTT), aPTT 1:1 mix with normal plasma, aPTT 1:1 incubated mix with normal plasma, aPTT 1:1 mix with saline, factor VIII activity, factor VIII Bethesda titer

Performing Location

Accredited Laboratory Partner

Testing Frequency

Contact Technical Support

Test Overview

Comprehensive evaluation for Factor VIII inhibitors, including titer and response. Used in advanced Hemophilia A cases.

Specimen Type

Plasma

Volume

3 mL

Specimen Container

Blue top (sodium citrate) tube

Patient Preparation

No special preparation is required for this test. You may eat, drink, and take your medications as normal, unless instructed otherwise by your healthcare provider.

Collection

Citrated Plasma samples should be collected by double centrifugation

Specimen Stability
Temperature Period
Frozen Contact Technical Support